Welcome to our dedicated page for CytomX Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics stock.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a leading oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics with its proprietary Probody庐 technology platform. Based in South San Francisco, CytomX leverages this platform to develop cancer immunotherapies that target clinically-validated and novel oncological targets. The unique Probody庐 therapeutics are designed to enhance the tumor-targeting capabilities of antibodies while minimizing toxicity in healthy tissues.
Probody庐 therapeutics operate by taking advantage of the unique conditions present in the tumor microenvironment, thereby improving both the efficacy and safety profiles of monoclonal antibody treatments, including cancer immunotherapies, antibody-drug conjugates (ADCs), and T-cell-recruiting bispecific antibodies. The company's innovative pipeline includes several promising candidates currently in various stages of development.
Among its recent achievements, CytomX is advancing its lead programs, CX-2051 and CX-801, into Phase 1 clinical studies. CX-2051 is an ADC that targets EpCAM-expressing tumors, including colorectal cancer, while CX-801 aims to overcome limitations associated with interferon-directed therapies. These candidates exemplify the versatility and productivity of CytomX's Probody庐 platform, promising significant advancements in cancer treatment.
CytomX has established strategic collaborations with industry leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to further enhance its research and development capabilities. As a result, the company is well-positioned to lead in the development of conditionally activated biologics designed for localized action within tumor microenvironments.
Financially, CytomX has made significant strides in cost control and strategic allocation of capital towards lead pipeline programs. In 2023, the company reduced its total operating expenses by $46.8 million, driven by workforce reductions and strategic pipeline prioritization. Research and development expenses decreased by $34.0 million, while general and administrative expenses decreased by $12.8 million.
For more information about CytomX and its innovative approach to cancer treatment, visit their official website at and follow them on LinkedIn and Twitter.
CytomX Therapeutics (CTMX) has completed its underwritten public offering of 14,285,714 shares at $7.00 per share, generating approximately $93.6 million in net proceeds. The offering was entirely sold by CytomX, which has also granted underwriters a 30-day option to purchase an additional 2,142,857 shares at the same price. The offering was conducted under an SEC registration statement filed in November 2018. The proceeds will be utilized to support the company鈥檚 ongoing development of cancer therapies utilizing its Probody technology platform.
CytomX Therapeutics (CTMX) has announced a public offering of 14,285,714 shares at $7.00 each, aiming for gross proceeds of $100 million before expenses. The company intends to allocate the proceeds toward the advancement of its Probody therapeutics pipeline, particularly for ongoing Phase 2 studies of CX-2009 and CX-2029. The offering is set to close around January 25, 2021, subject to customary conditions. This financial move reflects CytomX's commitment to developing innovative cancer treatments through its proprietary technology.
CytomX Therapeutics (CTMX) has announced a public offering of $75 million in common stock, with an additional $11.25 million option for underwriters. Proceeds will fund the advancement of its Probody庐 therapeutics pipeline, particularly the clinical development of CX-2009 and CX-2029, as well as IND enabling studies for CX-2043 and CX-904. The offering, managed by J.P. Morgan, Cowen, and Piper Sandler, is subject to market conditions and is expected to support ongoing cancer research.
CytomX Therapeutics (Nasdaq: CTMX) announced on January 15, 2021, the granting of stock options to two new employees for a total of 98,000 shares at an exercise price of $7.93, which reflects the closing price on that date. This grant is part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020, to attract new talent to the company. CytomX is focused on developing innovative Probody therapeutics for cancer treatment, emphasizing reduced toxicity and increased effectiveness.
CytomX Therapeutics (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. Additionally, the company will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event from January 11-14, 2021. Webcasts will be available on CytomX鈥檚 website, with archived replays accessible for 90 days post-conference. CytomX focuses on developing innovative Probody therapeutics for cancer, partnering with major pharmaceutical companies.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Mani Mohindru, PhD, to its board of directors. Dr. Mohindru, an experienced biotech executive, brings a strong background in finance and corporate strategy, previously serving as CEO of CereXis and CFO at Cara Therapeutics. Her expertise is expected to accelerate the development of CytomX's clinical pipeline, particularly its innovative Probody technology, aimed at creating selective cancer therapies. This leadership change comes as CytomX prepares for multiple critical data releases in 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to present two posters at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11. The presentations will focus on the clinical activity of CX-2009, a Probody drug conjugate, and its potential in treating advanced breast cancers. Notably, the data highlights the efficacy of CX-2009 alone and in combination with pacmilimab in HER2-non amplified breast cancer. The presentations occur on December 9 at 9:00 AM ET, showcasing CytomX's commitment to innovative cancer treatments.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., CEO, will participate in two virtual healthcare conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 18, 2020, at 10:15 a.m. ET. Additionally, the 32nd Annual Piper Sandler Virtual Healthcare Conference will occur on November 30, 2020, with a fireside chat available for on-demand viewing starting November 23, 2020, at 10:00 a.m. ET. Webcasts can be accessed on CytomX鈥檚 website with archived replays available for 90 days.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported its third quarter 2020 financial results, showing revenue of $17.8 million, a 66% increase from the same period in 2019. The company highlighted advancements in its clinical pipeline, including five Probody programs in the clinic, with four in Phase 2 studies. CX-2009 and CX-2029 are among the candidates being developed with initial data anticipated in late 2021. As of September 30, CytomX had $321.1 million in cash and equivalents, reflecting strong financial health.
CytomX Therapeutics (Nasdaq: CTMX) announced the initiation of a Phase 2 expansion study for CX-2029, a Probody drug conjugate targeting CD71, an important cancer target. This study will include various cancer types and is expected to enroll around 25 patients per cohort, focusing on overall response rate (ORR) and safety. The collaboration with AbbVie allows CytomX to earn up to $390 million in milestone payments. Initial data from the study is anticipated in late 2021, further showcasing CytomX's innovative approach to oncology.
FAQ
What is the current stock price of CytomX Therapeutics (CTMX)?
What is the market cap of CytomX Therapeutics (CTMX)?
What is CytomX Therapeutics, Inc.?
What is the Probody庐 technology platform?
Which are the leading programs of CytomX?
Who are CytomX's strategic partners?
What recent financial achievements has CytomX made?
What are the benefits of Probody庐 therapeutics?
How does CytomX's Probody庐 platform contribute to cancer treatment?
Where is CytomX Therapeutics located?
What types of cancer does CX-2051 target?
How can I learn more about CytomX's latest developments?
